Danaher Ranks 52nd on the 2021 Hurun Global 500 List, Driven by Strong Contributions to Pandemic Response and Strategic Expansions

SHANGHAI, Aug. 25, 2021 /PRNewswire/ -- Recently, Danaher Corporation, a global innovator in science and technology, ranked No. 52 on the 2021 Hurun Global 500 list, rising 13 places from last year.

On August 20, 2021, the Hurun Research Institute released the "2021 Hurun Global 500" list, which ranks the world's top 500 non-state-owned enterprises by market capitalization or valuation. The market capitalization of listed companies was calculated based on their closing prices on July 15, 2021, while the valuation of unlisted companies was estimated by referencing listed peers in the same industry or based on their most recent round of financing.

Among the 58 healthcare companies on the list, Danaher Corporation ranked 9th. Compared to the *2020 Hurun Global 500* (as of December 1, 2020), the average valuation of the listed healthcare companies increased by 20%. Danaher Corporation's value rose by 27%, exceeding the industry average. Since the list's data cutoff date to the present, Danaher Corporation's market capitalization has continued to grow, surpassing the $200 billion milestone for the first time in July.

Danaher's continued contributions to global COVID-19 vaccine, therapeutic, and diagnostic solutions have driven steady business growth. In the area of COVID-19 testing, international demand for Cepheid’s point-of-care PCR testing remains strong, and Cepheid is expected to ship approximately 50 million COVID-19 test kits in 2021.

Meanwhile, given the current pace of global COVID-19 vaccination, vaccine demand is expected to extend into the next year. In July 2021, two operating companies under Danaher Corporation, Cytiva and Pall, launched a sustained strategic growth initiative—investing $1.5 billion over the next two years and hiring 2,000 additional full-time employees to enhance manufacturing capacity and services across global regions, thereby meeting the growing demand for biotechnology solutions. This investment covers 13 facilities established by Cytiva and Pall worldwide, including the Pall Shunyi plant, which recently successfully shipped the first batch of Allegro single-use technology products produced in China. This facility is the first single-use technology production base established in Asia by Pall Group under the Danaher Life Sciences platform. From the acquisition of the factory to the shipment of the first batch of goods, the Pall project team applied the Danaher Business System (DBS) working methodology to complete the site selection, design, construction, validation, and commissioning of a 1,000-square-meter high-grade cleanroom in less than four months, with all initially shipped products supplied to COVID-19 vaccine projects in China. Meanwhile, Cytiva, a global leader in the life sciences sector, has added 1,500 employees worldwide within its first year of joining Danaher, substantially increasing production capacity to support customers in accelerating growth and innovation in the biopharmaceutical field. With performance growth exceeding 50%, Cytiva completed five strategic acquisitions throughout 2021, further enriching its product portfolio.

With the continued economic recovery across major global regions and end markets, Danaher’s Water Quality Management Platform and Product Identification Platform businesses also achieved steady growth, which accelerated alongside the resumption of customer operations and the investment and construction of large-scale projects.